NASDAQ:BTCY Biotricity (BTCY) Stock Price, News & Analysis → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Free BTCY Stock Alerts $1.20 0.00 (0.00%) (As of 11:18 AM ET) Add Compare Share Share Today's Range$1.20▼$1.2150-Day Range$0.92▼$1.6352-Week Range$0.70▼$4.37Volume5,083 shsAverage Volume82,600 shsMarket Capitalization$11.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Biotricity alerts: Email Address Ad Behind the MarketsCould this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.Access my full "Cut & Paste" profit analysis now. About Biotricity Stock (NASDAQ:BTCY)Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.Read More BTCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTCY Stock News HeadlinesApril 19, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 ClinicsApril 17, 2024 | investing.comBiotricity pilots cardiac tech at major hospital networkMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.April 16, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity Launches Cardiac Monitoring Pilot Program with Major Hospital NetworkMarch 28, 2024 | finanznachrichten.deLOBO EV and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMarch 2, 2024 | finance.yahoo.comBiotricity, Inc. (BTCY) Interactive Stock Chart - Yahoo FinanceFebruary 29, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity Receives Health Canada Clearance for BiotresFebruary 22, 2024 | finance.yahoo.comBiotricity, Inc. (NASDAQ:BTCY) Q3 2024 Earnings Call TranscriptMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.February 21, 2024 | benzinga.comBiotricity Stock (NASDAQ:BTCY) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comBiotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue EstimatesFebruary 20, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21stNovember 16, 2023 | finance.yahoo.comBiotricity, Inc. (NASDAQ:BTCY) Q2 2024 Earnings Call TranscriptNovember 14, 2023 | benzinga.comBiotricity Delivers Record Margins and Double Digit Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2024November 10, 2023 | finance.yahoo.comBiotricity to Host Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14thOctober 3, 2023 | finanznachrichten.deBiotricity, Inc.: Biotricity Announces Patient Filing for Cutting-Edge Biotres DeviceSeptember 13, 2023 | finance.yahoo.comBiotricity Unveils a New Digital Presence, Highlighting its Expanding Technology Portfolio and Cutting-Edge InnovationsAugust 30, 2023 | finanznachrichten.deBiotricity, Inc.: Biotricity Achieves $14 Million Revenue Run Rate in August 2023August 30, 2023 | finance.yahoo.comBiotricity Achieves $14 Million Revenue Run Rate in August 2023See More Headlines Receive BTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotricity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today5/08/2024Next Earnings (Estimated)7/04/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:BTCY CUSIPN/A CIK1630113 Webwww.biotricity.com Phone(800) 590-4155FaxN/AEmployees55Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.3899) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,660,000.00 Net Margins-125.43% Pretax Margin-125.43% Return on EquityN/A Return on Assets-233.67% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.10 Sales & Book Value Annual Sales$9.64 million Price / Sales1.17 Cash FlowN/A Price / Cash FlowN/A Book Value($2.27) per share Price / Book-0.53Miscellaneous Outstanding Shares9,420,000Free Float7,493,000Market Cap$11.30 million OptionableOptionable Beta1.54 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Waqaas Al-Siddiq Ph.D. (Age 39)Founder, President, CEO & Chairman Comp: $732kMr. S. John Ayanoglou (Age 57)Chief Financial Officer Comp: $305.75kMr. Andy WongVice President of OperationsDr. George N. NikopoulosDirector of Business DevelopmentMr. Matt ZabelVice President of Sales & StrategyMr. Amir AliChief Development OfficerMore ExecutivesKey CompetitorsNEXGELNASDAQ:NXGLPetVivoNASDAQ:PETVMicrobot MedicalNASDAQ:MBOTGlucoTrackNASDAQ:GCTKSTRATA Skin SciencesNASDAQ:SSKNView All CompetitorsInstitutional OwnershipAdvisor Resource CouncilBought 79,070 shares on 4/19/2024Ownership: 0.839%View All Institutional Transactions BTCY Stock Analysis - Frequently Asked Questions Should I buy or sell Biotricity stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biotricity in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BTCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTCY, but not buy additional shares or sell existing shares. View BTCY analyst ratings or view top-rated stocks. How have BTCY shares performed in 2024? Biotricity's stock was trading at $1.15 on January 1st, 2024. Since then, BTCY shares have increased by 4.3% and is now trading at $1.20. View the best growth stocks for 2024 here. Are investors shorting Biotricity? Biotricity saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 443,400 shares, an increase of 23.7% from the March 31st total of 358,400 shares. Based on an average trading volume of 96,900 shares, the short-interest ratio is presently 4.6 days. Currently, 5.6% of the company's shares are sold short. View Biotricity's Short Interest. When is Biotricity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our BTCY earnings forecast. How were Biotricity's earnings last quarter? Biotricity, Inc. (NASDAQ:BTCY) posted its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.07. The company had revenue of $2.97 million for the quarter, compared to the consensus estimate of $3 million. When did Biotricity IPO? Biotricity (BTCY) raised $15 million in an initial public offering (IPO) on Thursday, August 26th 2021. The company issued 5,000,000 shares at $3.00 per share. H.C. Wainwright & Co. acted as the underwriter for the IPO. Who are Biotricity's major shareholders? Biotricity's stock is owned by a number of retail and institutional investors. Top institutional investors include Advisor Resource Council (0.84%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Biotricity? Shares of BTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTCY) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward PressGold Set to EXPLODE!Gold Safe ExchangeThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotricity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
